Search clinical trials for: WT1 and PR1 Peptide Vaccine

Total 11400 results

National Heart, Lung, and Blood Institute (NHLBI)

Completed

Safety of Peptide Vaccination for Patients With Myelodysplastic Syndrome

Myelodysplastic Syndrome (MDS)

United States
M.D. Anderson Cancer Center
The Vaccine Company

Terminated

PR1 Vaccination in Myelodysplastic Syndrome (MDS)

Leukemia | Myelodysplastic Syndrome

United States
Sellas Life Sciences Group

Completed

WT-1 Analog Peptide Vaccine in Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL)

Acute Myeloid Leukemia | Acute Lymphoblastic Leukemia

United States
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Wilm's Tumor 1 (WT1) Peptide Vaccine for High Risk Hematologic Malignancy

Myelodysplastic Syndrome | Acute Myeloid Leukemia (AML) | Chronic Myeloid Leukemia (CML)

United States
Gitte Kronborg
Rigshospitalet, Denmark; Hvidovre University Hospital; Statens Serum Institut; Ministry...

Completed

Immunization With HIV-1 Peptides in Adjuvant for Treatment of Patients With Chronic HIV-infection (HIV-VAC)

HIV INFECTIONS

Denmark
National Liver Institute, Egypt

Unknown

Safety and Efficacy Study of CENV3 Vaccine to Protect Against HCV Infection (CENV3)

Vaccine Overdose of Undetermined Intent

Egypt
University Hospital, Antwerp
Kom Op Tegen Kanker; Stichting tegen Kanker

Recruiting

First-in-human Interleukin-15-transpresenting Wilms' Tumor Protein 1-targeting Autologous Dendritic Cell Vaccination in Cancer Patients (IL15-TransDC)

Esophageal Cancer | Ovarian Cancer | Pancreas Cancer | Liver Cancer

Belgium
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Peptide Vaccinations to Treat Patients With Low-Risk Myeloid Cancers

Acute Myeloid Leukemia (AML) | Myelodysplastic Syndrome (MDS) | Chronic Myeloid Leukemia (CML)

United States
Charite University, Berlin, Germany

Unknown

WT1 Peptide Vaccination in Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia | Myelodysplastic Syndrome

Germany
Charite University, Berlin, Germany

Unknown

WT1 Peptid Vaccination in Carcinomas

WT1 Expressing Carcinoma

Germany
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Safety and Immune Response to Three HIV Vaccine Schedules in Healthy, HIV-Uninfected Adults

HIV Infections

United States, Switzerland
University Hospital Southampton NHS Foundation...
Imperial College Healthcare NHS Trust; Royal Devon and Exeter NHS Foundation... and other collaborators

Completed

WT1 Immunity Via DNA Fusion Gene Vaccination in Haematological Malignancies by Intramuscular Injection Followed by Intramuscular Electroporation (WIN)

Leukaemia (Acute) | Leukaemia (Chronic) | Leukaemia (Acute Myeloid) | Leukaemia (Acute Lymphoblastic) | Leukaemia (Acute Promyelocytic)

United Kingdom
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

CMV-MVA Triplex Vaccination of Stem Cell Donors in Preventing CMV Viremia in Participants With Allogeneic Transplant

Hematopoietic and Lymphoid Cell Neoplasm | Hodgkin Lymphoma | Myelofibrosis | Chronic Lymphocytic Leukemia | Non-Hodgkin Lymphoma | Myelodysplastic Syndrome | Myelodysplastic/Myeloproliferative Neoplasm | Acute Myeloid Leukemia in Remission | Acute Lymphoblastic Leukemia in Remission | Cytomegalovirus... and other conditions

United States
M.D. Anderson Cancer Center
The Vaccine Company

Terminated

Proteinase 3 PR1 Peptide Mixed With Montanide ISA-51 VG Adjuvant and Administered With GM-CSF and PEG-INTRON(R)

Leukemia

United States
National Cancer Institute (NCI)

Completed

Booster Vaccination in Preventing Disease Recurrence in Previously Vaccinated Patients With Melanoma That Has Been Removed By Surgery

Stage IV Skin Melanoma | Recurrent Melanoma | Stage IIIB Skin Melanoma | Stage IIIC Skin Melanoma | Stage IIA Skin Melanoma | Stage IIB Skin Melanoma | Stage IIC Skin Melanoma | Stage IIIA Skin Melanoma | Stage IA Skin Melanoma | Stage IB Skin Melanoma

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Multi-antigen CMV-Modified Vaccinia Ankara Vaccine in Treating Pediatric Patients With Positive Cytomegalovirus Undergoing Donor Stem Cell Transplant

Hematopoietic Cell Transplant Recipient | Cytomegaloviral Infection

United States
University of Washington
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Stage IV HLA-A2 and HER2 Positive Breast or Ovarian Cancer Receiving Trastuzumab

Stage IV Breast Cancer | HER2/Neu Positive | HLA-A2 Positive Cells Present | Stage IV Ovarian Cancer

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Preventing Cytomegalovirus in Healthy Participants

Nonneoplastic Condition

United States
National Cancer Institute (NCI)

Completed

Vaccine Therapy Plus Immune Adjuvant in Treating Patients With Chronic Myeloid Leukemia, Acute Myeloid Leukemia, or Myelodysplastic Syndrome

Adult Acute Myeloid Leukemia in Remission | Accelerated Phase Chronic Myelogenous Leukemia | Chronic Phase Chronic Myelogenous Leukemia | Previously Treated Myelodysplastic Syndromes | Relapsing Chronic Myelogenous Leukemia | Refractory Anemia With Excess Blasts | Refractory Anemia With Excess...

United States
United Biomedical

Completed

A Phase I/II Safety and Immunogenicity Trial of UBI Microparticulate Monovalent (HIV-1 MN) Branched Peptide Vaccine in HIV-1 Seronegative Human Subjects

HIV Infections

United States
University of Maryland Greenebaum Cancer Center
National Cancer Institute (NCI)

Completed

Stem Cell Transplant, Chemotherapy, and Biological Therapy in Treating Patients With High-Risk or Refractory Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
The Vaccine Company

Unknown

Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia in Remission

Leukemia

United States
Egymedicalpedia

Completed

Evaluation of the Effect of Self-Assembling Peptide P11-4

Dental Caries

Egypt
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Completed

Vaccine Therapy Using Melanoma Peptides for Cytotoxic T Cells and Helper T Cells in Treating Patients With Metastatic Melanoma

Melanoma (Skin)

United States
Michael Morse, MD
Immunotope

Completed

A Phase I Study of Ovarian Cancer Peptides Plus GM-CSF and Adjuvant With Ovarian, Tubal or Peritoneal Cancer

Epithelial Ovarian, Tubal or Peritoneal Cancer

United States
COL George Peoples, MD, FACS

Completed

Phase I/IIa Trial of Folate Binding Protein Vaccine in Ovarian Cancer

Ovarian Cancer | Endometrial Cancer | Peritoneal Cancer | Fallopian Cancer

United States
Imperial College London
Aristotle University Of Thessaloniki

Completed

Anti-hypertensive Medication Dosing Regimen in Effective Blood Pressure Control (HARMONY)

Hypertension

Greece, United Kingdom
City of Hope Medical Center
National Cancer Institute (NCI); Diavax Biosciences

Active, not recruiting

Multi-antigen CMV-MVA Triplex Vaccine in Reducing CMV Complications in Patients Previously Infected With CMV and Undergoing Donor Hematopoietic Cell Transplant

Hodgkin Lymphoma | Myelofibrosis | Lymphoblastic Lymphoma | Chronic Lymphocytic Leukemia | Non-Hodgkin Lymphoma | Myelodysplastic Syndrome | Lymphadenopathy | Myeloproliferative Neoplasm | Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Acute Myeloid Leukemia in Remission | Accelerated Phase... and other conditions

United States
University of California, Davis
National Cancer Institute (NCI); IO Biotech

Recruiting

IDO and PD-L1 Peptide Based Immune-Modulatory Therapeutic (IO102-IO103) in Combination With Pembrolizumab for BCG-Unresponsive or Intolerant, Non-Muscle Invasive Bladder Cancer

Stage 0a Bladder Cancer AJCC v8 | Stage 0is Bladder Cancer AJCC v8 | Stage I Bladder Cancer AJCC v8 | High Risk Non-Muscle Invasive Bladder Urothelial Carcinoma

United States
Michael Morse, MD

Terminated

A Phase I Study of WT1 Peptides to Induce Anti-Leukemia Immune Responses Following Transplantation (WT-1)

Acute Lymphoblastic Leukemia (ALL) | Myelodysplastic Syndrome (MDS) | Acute Myelogenous Leukemia (AML) | B Cell Malignancies | Chronic Myelogenous Leukemia (CML)

United States
University Hospital Tuebingen

Not yet recruiting

Multi-peptide Vaccination Adjuvanted With XS15 in Acute Myeloid Leukemia Patients (AML-VAC-XS15)

Acute Myeloid Leukemia, Adult
Zhujiang Hospital
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University; Shenzhen Geno-Immune...

Recruiting

CAR-T Cells Combined With Peptide Specific Dendritic Cell in Relapsed/Refractory Leukemia/MDS

Myelodysplastic Syndromes | Leukemia, Acute Myelogenous (AML) | Leukemia, Acute Lymphocytic (ALL)

China
COL George Peoples, MD, FACS
M.D. Anderson Cancer Center

Completed

Phase Ib Trial of Two Folate Binding Protein Peptide Vaccines (E39 and J65) in Breast and Ovarian Cancer Patients (J65)

Breast Cancer | Ovarian Cancer

United States
National Institute of Allergy and Infectious Diseases...
HIV Vaccine Trials Network; IPPOX Foundation; EuroVacc Foundation; Global Solutions...

Withdrawn

Evaluating the Safety and Immune Response to Two HIV Vaccine Regimens in Healthy, HIV-Uninfected Adults in the United States and South Africa

HIV Infections
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity Study of Antibody Persistence and Booster Effect of DTaP-HB PRP~T Combined Vaccine in Filipino Infants

Hepatitis B | Pertussis | Tetanus | Diphtheria | Influenza

Philippines
African Malaria Network Trust
London School of Hygiene and Tropical Medicine

Unknown

A Phase Ib Trial of MSP 3 LSP in 1-2 Year Old Children in Burkina Faso (MSP3LSP)

Malaria

Burkina Faso
Sidney Kimmel Comprehensive Cancer Center at Johns...

Recruiting

Prophylactic Peptide Vaccine in Advanced ALK+ NSCLC

NSCLC Stage IV | ALK Fusion Protein Expression

United States
African Malaria Network Trust
London School of Hygiene and Tropical Medicine

Unknown

Phase Ib Trial of MSP3 LSP in Children in Tanzania (MSP3TN)

Malaria

Tanzania
Sellas Life Sciences Group
Merck Sharp & Dohme LLC; Cancer Insight, LLC

Active, not recruiting

Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers

Colorectal Cancer | Ovarian Cancer | Acute Myelogenous Leukemia | Small-cell Lung Cancer | Triple-negative Breast Cancer

United States
University of Virginia
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Metastatic Melanoma

Melanoma (Skin)

United States
Sanofi

Completed

A Study of DTaP//PRP-T Combined Vaccine (ACTACEL) Versus Local DTaP and Act-HIB Monovalent Vaccine in Healthy Infants

Pertussis | Tetanus | Diphtheria | Haemophilus Influenzae Type B

China
University Hospital Tuebingen
Cooperative Weichteilsarkom Study Group; Deutsches Konsortium fürTranslationale... and other collaborators

Recruiting

Personalized Vaccination in Fusion+ Sarcoma Patients (PerVision) (PerVision)

Ewing Sarcoma | Rhabdomyosarcoma | Synovial Sarcoma

Germany
zeinab ahmed yousif hasan ashour

Recruiting

Personalized Cancer Vaccine in Egyptian Cancer Patients (PROVE)

Hepatocellular Carcinoma

Egypt
Herbert Lyerly

Recruiting

Cancer Peptides Plus GM-CSF and Adjuvant in Breast Cancer

Breast Cancer

United States
Inge Marie Svane

Recruiting

Combination Therapy With Nivolumab and PD-L1/IDO Peptide Vaccine to Patients With Metastatic Melanoma

Metastatic Melanoma

Denmark
H. Lee Moffitt Cancer Center and Research Institute
National Institutes of Health (NIH)

Completed

PSMA and TARP Peptide Vaccine With Poly IC-LC Adjuvant in HLA-A2 (+) Patients With Elevated PSA After Initial Definitive Treatment

Prostate Cancer

United States, Puerto Rico
Hadassah Medical Organization
Vaxil Therapeutics Ltd.

Withdrawn

A Novel Vaccine for the Treatment of MUC1-expressing Tumor Malignancies

Multiple Myeloma | Tumors

Israel
Lene Meldgaard Knudsen

Completed

Vaccination With PD-L1 Peptide Against Multiple Myeloma

Multiple Myeloma

Denmark
The Vaccine Company

Unknown

Vaccine Therapy and GM-CSF in Treating Patients With Low-Risk or Intermediate-Risk Myelodysplastic Syndrome

Myelodysplastic Syndromes

United States
National Institute of Allergy and Infectious Diseases...

Completed

A Phase I Trial To Evaluate the Safety and Immunogenicity of the UBI HIV-1MN PND Peptide Immunogen, Given by IM Injection, in Combination With the UBI Microparticulate Monovalent HIV-1 MN Branched Peptide Given Orally, in HIV-1 Uninfected Volunteers.

HIV Infections

United States

Search clinical trials for: WT1 and PR1 Peptide Vaccine

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in United Arab Emirates

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations